Select a medication above to begin.
Cuvitru
immune globulin (human)
Black Box Warnings .
Thrombosis
may occur w/ immune globulin products; risk factors incl. advanced age, prolonged immobilization, hypercoagulable conditions, venous or arterial thrombosis hx, estrogen use, indwelling central vascular catheter, hyperviscosity, and cardiovascular dz risk; thrombosis may occur in pts w/o risk factors; use minimum dose and infusion rate practicable in pts at risk; ensure adequate hydration before admin; monitor for s/sx thrombosis and assess blood viscosity in pts w/ hyperviscosity risk
Adult Dosing .
Dosage forms: INJ
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing
primary immunodeficiency
- [frequent dosing (2-7x/wk)]
- Dose: frequent SCIG dose = [last IVIG dose (g) or last SCIG/hyaluronidase dose (g) x 1.3] divided by last IVIG or SCIG/hyaluronidase dosing interval (wk) divided by the desired number of doses per wk; Start: 1wk after receiving last IVIG or SCIG/hyaluronidase dose; Alt: divide last weekly SCIG dose by the desired number of doses per wk; Info: adjust dose based on trough IgG levels and clinical response; give IVIG dose x1 ASAP w/in 6 days if measles exposure; give minimum total weekly dose 230 mg/kg/wk if measles exposure risk
- [weekly dosing]
- Dose: weekly SCIG dose = [last IVIG dose (g) or last SCIG/hyaluronidase dose (g) x 1.3] divided by last IVIG or SCIG/hyaluronidase dosing interval (wk); Start: 1wk after receiving last IVIG or SCIG/hyaluronidase dose; Alt: maintain previous weekly SCIG dose; Info: adjust dose based on trough IgG levels and clinical response; give IVIG dose x1 ASAP w/in 6 days if measles exposure; incr. maint. dose to at least 230 mg/kg/dose IV qwk if measles exposure risk
- [biweekly dosing (q2wk)]
- Dose: biweekly SCIG dose = weekly SCIG dose x2; Start: 1wk after receiving last IVIG or SCIG/hyaluronidase dose; Info: adjust dose based on trough IgG levels and clinical response; give IVIG dose x1 ASAP w/in 6 days if measles exposure; give minimum total weekly dose 230 mg/kg/wk if measles exposure risk
renal dosing
- [see below]
- renal impairment: not defined, consider lower, more frequent dosing
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing
primary immunodeficiency
- [frequent dosing (2-7x/wk), 2 yo and older]
- Dose: frequent SCIG dose = [last IVIG dose (g) or last SCIG/hyaluronidase dose (g) x 1.3] divided by last IVIG or SCIG/hyaluronidase dosing interval (wk) divided by the desired number of doses per wk; Start: 1wk after receiving last IVIG or SCIG/hyaluronidase dose; Alt: divide last weekly SCIG dose by the desired number of doses per wk; Info: adjust dose based on trough IgG levels and clinical response; give IVIG dose x1 ASAP w/in 6 days if measles exposure; give minimum total weekly dose 230 mg/kg/wk if measles exposure risk
- [weekly dosing, 2 yo and older]
- Dose: weekly SCIG dose = [last IVIG dose (g) or last SCIG/hyaluronidase dose (g) x 1.3] divided by last IVIG or SCIG/hyaluronidase dosing interval (wk); Start: 1wk after receiving last IVIG or SCIG/hyaluronidase dose; Alt: maintain previous weekly SCIG dose; Info: adjust dose based on trough IgG levels and clinical response; give IVIG dose x1 ASAP w/in 6 days if measles exposure; incr. maint. dose to at least 230 mg/kg/dose IV qwk if measles exposure risk
- [biweekly dosing (q2wk), 2 yo and older]
- Dose: biweekly SCIG dose = weekly SCIG dose x2; Start: 1wk after receiving last IVIG or SCIG/hyaluronidase dose; Info: adjust dose based on trough IgG levels and clinical response; give IVIG dose x1 ASAP w/in 6 days if measles exposure; give minimum total weekly dose 230 mg/kg/wk if measles exposure risk
renal dosing
- [see below]
- renal impairment: not defined, consider lower, more frequent dosing
- HD/PD: not defined
hepatic dosing
- [not defined]